Volume | 0 |
|
|||||
News | - | ||||||
Day High | Low High |
||||||
Day Low |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
NeuroBo Pharmaceuticals Inc | NRBO | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
3.23 |
Trades | Volume | Avg Volume | 52 Week Range |
---|---|---|---|
0 | 0 | - | 2.8888 - 6.7499 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
- | 0 | $ 3.23 | USD |
NeuroBo Pharmaceuticals Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
15.67M | 4.85M | - | 0 | -12.47M | -2.57 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
NeuroBo Pharmaceuticals News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical NRBO Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 3.10 | 3.4999 | 2.99 | 3.09 | 22,592 | 0.13 | 4.19% |
1 Month | 4.05 | 4.12 | 2.99 | 3.49 | 24,127 | -0.82 | -20.25% |
3 Months | 4.91 | 6.7499 | 2.99 | 5.32 | 130,382 | -1.68 | -34.22% |
6 Months | 3.44 | 6.7499 | 2.90 | 5.32 | 708,432 | -0.21 | -6.10% |
1 Year | 5.2016 | 6.7499 | 2.8888 | 5.00 | 489,872 | -1.97 | -37.90% |
3 Years | 842.40 | 1,576.80 | 2.8888 | 260.24 | 1,038,918 | -839.17 | -99.62% |
5 Years | 2,196.00 | 7,200.00 | 2.8888 | 321.73 | 751,988 | -2,192.77 | -99.85% |
NeuroBo Pharmaceuticals Description
NeuroBo Pharmaceuticals Inc is a clinical-stage biotechnology company focused on developing and commercializing multi-modal disease-modifying therapies for viral, neuropathic, and neurodegenerative diseases, has a current portfolio of four drug candidates. The company's acquired ANA001 candidate is a proprietary oral niclosamide formulation in development as a treatment for patients with moderate to severe COVID-19. ANA001 is being studied in a 60-subject Phase 2/3 clinical trial conducted at up to 20 clinical sites in the USA. The company's NB-01 candidate has been shown in a Phase 2 study to significantly reduce pain symptoms associated with painful diabetic neuropathy (PDN), with a superior safety profile when compared to currently available treatments. |